BRD2 Antibody (12C2E4)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-14861
Key Product Details
Validated by
Independent Antibodies
Species Reactivity
Validated:
Human
Predicted:
Bovine (100%), Canine (100%), Chimpanzee (100%), Chinese Hamster (100%), Equine (100%), Guinea Pig (100%), Monkey (100%), Mouse (100%), Orangutan (100%), Porcine (100%). Backed by our 100% Guarantee.
Applications
Immunoprecipitation, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # 12C2E4
Concentration
1.0 mg/ml
Product Specifications
Immunogen
This antibody maps to a region between residue 213 and 263 of human Proteasome (Prosome, Macropain) Subunit, Alpha Type, 1 using the numbering given in entry NP_002777.1 (GeneID 5682).
Reactivity Notes
Based on 100% sequence identity, this antibody is predicted to react with Gorilla, Panda.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Scientific Data Images for BRD2 Antibody (12C2E4)
Immunoprecipitation: BRD2 Antibody (12C2E4) [NBP2-14861]
Immunoprecipitation: BRD2 Antibody (12C2E4) [NBP2-14861] - Detection of human BRD2 by WB of immunoprecipitates from HEK293T lysate. Antibodies: Mouse monoclonal anti-BRD2 [12C2E4] (NBP2-14861) and rabbit anti-BRD2 antibody (NBP1-30474). Secondary: HRP-conjugated goat anti-mouse IgG.Western Blot: BRD2 Antibody (12C2E4) [NBP2-14861] -
Western Blot: BRD2 Antibody (12C2E4) [NBP2-14861] - Whole cell lysate (50 µg) from HEK293T, HeLa, MCF-7,Hep-G2, and Jurkat cells prepared using NETN lysis buffer.Antibody: Mouse anti-BRD2 monoclonal antibody [12C2E4] used at 1:1000. Secondary: HRP conjugated goat anti-mouse IgG. Chemiluminescence with an exposure time of 30 seconds.Lower Panel: Rabbit anti-COPB2 antibody .Applications for BRD2 Antibody (12C2E4)
Application
Recommended Usage
Immunoprecipitation
20 ul/mg lysate
Western Blot
1:1000
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris-buffered Saline, 0.1% BSA
Preservative
0.09% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: BRD2
BRD2 and the other BET proteins have been implicated in a variety of diseases and pathologies. The BET proteins are known drivers of cancer through mutation and over-expression (1). Recently, in studies examining the role of Type 2 diabetes and obesity in breast cancer progression, the BET proteins have been shown to be critical regulators of metabolism and metastasis and are co-activators for the transcription of genes that encode pro-inflammatory cytokines in immune cells infiltrating the breast cancer microenvironment (1). Accordingly, knockdown of Brd2 in mice protected the animals from developing Type 2 diabetes and stopped the inflammatory response typically elicited by obesity (4). BRD2 is also highly expressed in the brain and the gene has been shown to play a role in juvenile myoclonic epilepsy, a common form of epilepsy that typically reveals itself during adolescence (5). In addition to the brain, BRD2 is highly expressed in the bone marrow and consequently its kinase activity has been shown to increase upon cellular proliferation and is significantly elevated in the peripheral blood lymphocytes of lymphoma patients (2, 3).
Research has been done to better understand protein interactions with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the novel coronavirus disease 2019 (COVID-19), as possible targets for drug therapies. It was recently described that that the transmembrane envelope protein (E) of SARS-CoV-2 binds to both BRD2 and BRD4, suggesting that bromodomain inhibitors could be a potential drug target (6). More specifically, the bromodomain inhibitors could be relevant regarding the secondary immune-related consequences that arise from SARS-CoV-2 infection (6). Bromodomain inhibitors are currently the focus of multiple clinical trials as a potential therapeutic in cancer and pulmonary arterial hypertension (6).
References
1. Andrieu, G.P., Shafran, J.S., Deeney, J.T., Bharadwaj, K.R., Rangarajan, A., & Denis, G.V. (2018). BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. J Leukoc Biol. https://doi:10.1002/JLB.5RI0917-380RR
2. BRD2 bromodomain 2 (human), NCBI
3. Taniguchi, Y. (2016). The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int J Mol Sci. https://doi:10.3390/ijms17111849
4. Wang, F., Deeney, J.T., & Denis, G.V. (2013). Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam Horm. https://doi:10.1016/B978-0-12-407766-9.00003-1
5. Gilsoul, M., Grisar, T., Delgado-Escueta, A.V., de Nijs, L., & Lakaye, B. (2019). Subtle Brain Developmental Abnormalities in the Pathogenesis of Juvenile Myoclonic Epilepsy. Front Cell Neurosci. https://doi:10.3389/fncel.2019.00433
6. Harrison, C. (2020). Drug researchers pursue new lines of attack against COVID-19. Nat Biotechnol. https://doi.org/10.1038/d41587-020-00013-z
Long Name
Bromodomain Containing 2
Alternate Names
FSRG1, RING3, RNF3
Gene Symbol
BRD2
UniProt
Additional BRD2 Products
Product Documents for BRD2 Antibody (12C2E4)
Product Specific Notices for BRD2 Antibody (12C2E4)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...